![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Analysis of HCV Genotype 1 Variants Detected During Monotherapy and Combination Therapy With Next Generation HCV Direct-Acting Anti viral Agents ABT-493 and ABT-530 "........COMBINATION THERAPY (SURVEYOR-I PART 1, PHASE 2 DOSE-RANGING STUDY) .....All patients with baseline NS3 or NS5A variants achieved SVR12 (Study SVR12: 99%)"
|
|
|
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco, CA
Teresa Ng, Tami Pilot-Matias, Rakesh Tripathi, Gretja Schnell, Thomas Reisch, Jill Beyer, Tanya Dekhtyar, Armen Asatryan, Federico Mensa, Andrew Campbell, Jens Kort, Christine Collins
AbbVie Inc., North Chicago, Illinois, United States
![AASLD1.gif](../images/111815/111815-3/AASLD1.gif)
![AASLD2.gif](../images/111815/111815-3/AASLD2.gif)
![AASLD3.gif](../images/111815/111815-3/AASLD3.gif)
![AASLD4.gif](../images/111815/111815-3/AASLD4.gif)
![AASLD5.gif](../images/111815/111815-3/AASLD5.gif)
![AASLD6.gif](../images/111815/111815-3/AASLD6.gif)
![AASLD7.gif](../images/111815/111815-3/AASLD7.gif)
![AASLD8.gif](../images/111815/111815-3/AASLD8.gif)
![AASLD9.gif](../images/111815/111815-3/AASLD9.gif)
![AASLD10.gif](../images/111815/111815-3/AASLD10.gif)
![AASLD11.gif](../images/111815/111815-3/AASLD11.gif)
![AASLD12.gif](../images/111815/111815-3/AASLD12.gif)
![AASLD13.gif](../images/111815/111815-3/AASLD13.gif)
![AASLD14.gif](../images/111815/111815-3/AASLD14.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|